Access to subspecialty care may be diffi cult for patients with liver disease, but it is unknown whether access infl uences outcomes among this population. Our objectives were to determine rates and predictors of access to ambulatory gastrointestinal (GI) subspecialty care for patients with liver disease and to determine whether access to subspecialty GI care is associated with better survival.
INTRODUCTION
Liver disease is a growing medical problem both in the Department of Veterans Aff airs (VA) Health Systems, as well as in the United States and worldwide. Th e prevalence of hepatitis C is estimated at 5% in the VA ( 1 ) . Approximately 30% of Americans likely have non-alcoholic fatty liver disease ( 2 ) . Worldwide, cirrhosis is thought to be the eighth leading cause of death ( 3 ) . Because liver disease may require complex care, referral to subspecialty care in gastroenterology/hepatology (GI) is oft en warranted. However, which factors determine whether patients ultimately receive care from GI subspecialists and whether this impacts overall survival is not fully known.
Patients with liver disease may experience problems with access to subspecialty care, due to many factors such as geographic clustering of specialists in tertiary-care centers. Although access to healthcare has been sparsely studied in liver disease, it has been recognized anecdotally as a problem in some practice areas. For example, despite the existence of multiple grade 1/class 1 recommendations, adherence to guideline-based care for patients with some forms of chronic liver disease remains low (4) (5) (6) (7) (8) . Only 38% of patients with cirrhosis nationwide undergo screening for hepatocellular carcinoma, and only 30% of those with spontaneous bacterial peritonitis receive antibiotics for secondary prophylaxis ( 7, (9) (10) (11) (12) (13) .
One possible cause for such poor guideline adherence may be a lack of access to subspecialty care, which has been shown to infl uence treatment decisions in a variety of gastroenterological conditions ( 7, 9, 10, (12) (13) (14) (15) (16) . As such, innovative coordination and communication interventions have been designed to increase access to specialty care and knowledge ( 11, 17 ) . Th e Department of Veterans Aff airs (VA) recently implemented the Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) program, a knowledge network linking primary care physicians to tertiary-care subspecialists. In 2011, SCAN-ECHO began for liver disease within Veterans Integrated Service Network (VISN) 11 . Th e goal of this study was to examine access to subspecialty care and its impact on survival prior to implementation of SCAN-ECHO, in order to establish a baseline for future comparison and develop a better understanding of the access problem. Our aims were (i) to determine rates and predictors of access to ambulatory GI subspecialty care for patients with liver disease and (ii) to determine whether access to ambulatory GI subspecialty care was associated with better survival.
METHODS

Population
Th e cohort included all adult patients over the age of 18 years within the VISN 11 with an International Classifi cation of Diseases, 9th Edition (ICD-9) code for liver disease entered into the electronic medical record between 1 January 2000 and 31 May 2011 (n=38,709). VISN 11 is one of the 21 integrated service networks within the VA healthcare system and provides inpatient and outpatient care for veterans within a 90,100 mi 2 geographic area including Michigan, central Indiana, and northwest Ohio. Liver disease was broadly defi ned as the presence of any one of the several ICD-9 codes for liver diseases including hepatitis C and cirrhosis (see Supplementary Appendix A online). We specifi cally chose ICD-9 codes that were the most common reasons for referral to GI subspecialty care and that, for the most frequent diagnoses (hepatitis C and cirrhosis), have been previously validated within the VA system ( 18 ) . Cirrhosis patients were defi ned as patients with at least two inpatient or outpatient ICD-9 codes for cirrhosis (571.2, 571.5, 571.6) or one ICD-9 code for cirrhosis plus either a code for a cirrhosis complication (456.0, 456.1, 456.21, 572.2, 572.3, 572.4, 572.8, 789.5), or an aspartate aminotransferase/platelet ratio index >2 ( 7 ) . To account for late referral bias, i.e., very sick patients who may have died before being able to complete an ambulatory GI clinic visit, we excluded all patients who died within 30 days of their index diagnosis (n=622). Patients can be enrolled in VA care for medication benefi ts only, which requires only a single yearly visit with a PCP with the remainder of their care provided in non-VA facilities. In order to control for misclassifi cation bias, we further excluded all patients with 10 or fewer visits who also had no GI clinic visit and no inpatient stay over the 10-year study period (n=1,161), which resulted in a fi nal cohort size of n =28,861 (see Supplementary Figure S1 online).
Th is analysis was conducted as part of an evaluation of the Chronic Liver Disease SCAN-ECHO program at VA Ann Arbor Healthcare System (VAAAHS). It was deemed non-research under VHA Handbook 1058.05 and conducted under the approval of clinical leadership at VAAAHS.
Outcome and predictors
To evaluate access, we defi ned the presence of a GI clinic visit at any time point within the study period aft er diagnosis, as indicated by the presence of codes in the electronic record indicating a completed GI or Liver clinic visit. Within VISN 11 during the time period studied, subspecialty care by either a gastroenterologist or a hepatologist was within these two clinic designations. For the purposes of this study, "diagnosis" refl ects the fi rst time a liver disease code appears for a given patient during the study period. Five-year survival was determined based on the VA's Benefi ciary Identifi cation Records Locator Subsystem (BIRLS) Death File. Deaths were recorded from the beginning of the study period until 31 May 2011.
Predictors of access were defi ned as follows: demographic predictors were age at diagnosis, gender, and race/ethnicity. Urban vs. rural patient residence was determined based on VA Planning Systems Support Group geocoding ( 19 ) . GI referral rates were also calculated and were defi ned as the presence of a request in the electronic medical record for consultation with a GI physician. Referrals that were non-liver specifi c (e.g., for colonoscopy only) were excluded. Given that most GI subspecialists are clustered at tertiary-care sites, the driving distance from the patient's home address to the nearest tertiary-care site was measured in miles. Tertiary-care sites within VISN 11 are Ann Arbor, MI, Indianapolis, IN, and Detroit, MI. Th e alanine aminotransferase value used was the highest alanine aminotransferase level within 365 days, but prior to diagnosis, to account for the triggers for consultation. Th e bilirubin level used was the value closest to diagnosis date and within 180 days prior to diagnosis to account for severity of liver disease. Elixhauser comorbidity scores were calculated using diagnosis codes present 365 days prior to the fi rst liver disease diagnosis and excluded liver disease and alcoholism ( 20 ) . Cirrhosis comorbidities including ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, variceal bleed, hepatocellular carcinoma, and hepatic encephalopathy were determined by ICD-9-CM codes (see Supplementary Appendix A ). A supplemental analysis was performed that divided the cohort into two groups, low-grade and high-grade fi brosis, based on the FIB-4 score, a serologic scoring system for fi brosis that utilizes common lab values (age, platelet count, aspartate aminotransferase, and alanine aminotransferase) to create a score that is predictive of high-grade fi brosis ( 21 ) .
Statistical analysis
Th e GI referral rate was calculated with the number of patients in the cohort with at least one GI consult request in the electronic LIVER VOLUME 111 | JUNE 2016 health record aft er diagnosis as the numerator and total cohort population as the denominator. GI visit rate was calculated as the number of patients with a completed GI visit code at any time aft er diagnosis as the numerator with total number of patients in the cohort as the denominator. Pearson's χ 2 -test, Wilcoxon rank-sum, and Student's t -test were used as appropriate for bivariate analyses of categorical and continuous predictors of access, respectively. Multivariable logistic regression was performed to determine independent predictors of a GI visit. All relevant variables were included in the fi nal model, regardless of their statistical signifi cance in bivariate testing.
In order to determine whether subspecialty access was independently associated with mortality, Cox proportional hazard ratios were calculated with multivariate models identical to those used in prior regression for Aim i. To adjust for diff erences between the patients who received a visit and those who did not, a propensity score was created by fi tting a logistic regression model for receipt of a GI visit based on 23 diff erent predictors including demographics, geographic location, disease state and severity, and receipt of selected imaging and procedures (predictors used were identical to those used in the multivariable regression in Table 2 ). A ratio of 3:1 nearest neighbor matching with replacement was used with a caliper of 0.2 ( 22 ) . Supplemental analyses including multivariate regression and propensity-adjusted analysis were performed on the low-grade fi brosis and high-grade fi brosis cohorts, respectively, using the same methodology as described above. Statistical analyses were performed using STATA version 12.1 (College Station, TX).
RESULTS
Characteristics of the cohort are included in Table 1 . Aft er application of inclusion and exclusion criteria (see Supplementary  Figure S1 ), 28,861 patients were diagnosed with liver disease over the 10-year study time frame with 10,710 (37%) receiving a GI clinic visit. Th e average age at fi rst diagnosis was 56 years with those receiving a clinic visit being younger than those who did not (54 years vs. 58 years, P <0.001). Ninety-six percent were male and two-thirds lived in an urban area. As of 31 May 2011, 24% of the cohort had died. Th irty-fi ve percent had a hepatitis C diagnosis and 9% had a diagnosis of cirrhosis. For those with hepatitis C, 44% received a clinic visit. Th e average travel distance from the patient's home to the closest tertiary-care site was 79 mi, with patients receiving a clinic visit traveling 69 mi vs. 84 mi for those who did not ( P <0.001). Overall, 55% of the entire cohort received a GI referral, whereas 37% received a GI clinic visit. Th e mean number of GI visits per patient was 4.41 (s.d. 5.82), whereas the median number of GI visits per patient was 2.00 (interquartile range 1.00-5.00).
On multivariable logistic regression (see Table 2 ), older patients (odds ratio (OR) 0.98, P <0.001) and those with more comorbidities (OR 0.98, P =0.01) were less likely to be seen in clinic. Furthermore, patients with certain complications of cirrhosis, such as thrombocytopenia (OR 0.60), hepatorenal syndrome (OR 0.3), hepatocellular carcinoma (OR 0.4), and ascites (OR 0.7), were less likely to be seen in clinic (all P <0.001). Caucasians (OR 1.1, P =0.03) and African-Americans (OR 1.4, P <0.001) were more likely to be seen in clinic, as were patients in urban locations (OR 1.1, P <0.001) and those with HCV and cirrhosis diagnoses prior to their initial GI visit (OR 1.5 and 3.5, respectively; P <0.001). Patients who lived further from a tertiary-care site were less likely to be seen in clinic (OR 0.998/mi, P <0.001). In the overall cohort, patients with an ambulatory GI visit at any time aft er diagnosis had a lower likelihood of death at 5 years than those without a GI visit when compared with propensity-scorematched controls (hazard ratio 0.81, P <0.001). Th e propensityadjusted survival curves are shown in Figure 1 . To determine whether there was improved survival with a greater number of GI visits (a "dose-response"), we performed an additional propensityadjusted survival analysis of patients above or below the median number of GI visits. Patients with 1-2 GI visits had poorer 5-year survival compared with patients who had >2 GI visits (hazard ratio 0.72, P <0.001). To determine whether there was a diff erence in survival between patients with more severe chronic liver disease, additional propensity analyses of low-grade and high-grade fi brosis cohorts were performed. Patients with both low-grade and high-grade fi brosis had improved survival at 5 years (hazard ratio 0.78 and 0.82, P <0.001 respectively).
DISCUSSION
In this large cohort of VA patients diagnosed with liver disease, receipt of an ambulatory GI clinic visit was associated with improved survival at 5 years in a propensity-score adjusted Mellinger et al.
of a mortality benefi t in this group may be unrelated to the GI clinic visit. Taken together, these results suggest that access to GI subspecialty care for patients with liver disease may improve outcomes, but more research is required to confi rm the presence of this association in other healthcare systems and to determine the causes behind such an association. Precisely how subspecialist access may infl uence survival is unknown, but improved quality of care, higher rates of screening for hepatocellular carcinoma, greater familiarity with and rapid recognition of complications, and greater likelihood of referral for liver transplant when appropriate may all have a role ( 15, 23 ) . However, access to care is a multifaceted concept. It has been conceptualized as containing fi ve diff erent domains: availability, accessibility, accommodation, aff ordability, and acceptability ( 24 ) . Although the goal of eff orts to improve access is to connect patients with the medical care that they need, oft en culminating in the traditional clinic visit, there are many diff erent barriers to access that patients must overcome before arriving in the clinic. Th ese include fi nancial barriers, insurance status, lack of social support, perceived stigma associated with liver disease, and patient-related beliefs about their disease, as well as poor care coordination to name a few ( 5, 25 ) . Although our models accounted for many of these factors, there are likely patient, provider, and cliniclevel traits that are not captured and that may help confi rm and further characterize this association, as well as reasons for it.
Th e burden of liver disease is increasing nationwide, and this, coupled with the demand for newly available hepatitis C treatments, means that access to subspecialty care for patients with liver disease will continue to be important ( 26 ) . To address access issues, innovative communication technologies are being developed and implemented to bridge the gap between patients and subspecialists. Programs such as SCAN-ECHO, e-referral, e-consults, and other telehealth initiatives are emerging as important ways for patients with a variety of chronic diseases including hepatitis C and liver disease to obtain care ( 11, 17, 27 ) . Within VISN 11, for example, implementation of SCAN-ECHO for patients with liver disease saved patients 187 mi in travel on average ( 28 ) . Despite this, geographic barriers remain important. Our fi nding that patients with hepatitis C and cirrhosis were more likely to be referred and to complete visits suggests a place for projects that extend subspecialty knowledge on these diseases from the academic health center to patients' and providers' locations. As newer, more tolerable, all-oral regimens with shorter treatment durations and fewer side eff ects become available for hepatitis C treatment, demand for access to subspecialty care may rise.
Th ere were several limitations to our study. First, it was conducted within the VA healthcare system, which may diminish generalizability of results given the markedly diff erent healthcare delivery system within which patients received care. Patients are eligible for VA benefi ts if they have served in the US military branches and, as such, are more likely to be male, as refl ected in our demographic information. As a consequence, our fi ndings may not be generalizable to female patients. Second, although all patients within the cohort received care within the VA healthcare system, we were unable to capture care that may have been provided by non-VA providers, as some Veteran patients carry analysis. Furthermore, receipt of >2 visits over the time period was associated with improved survival compared with those who had fewer visits. Patients who lived farther from tertiary-care sites were less likely to be seen, whereas those who had diagnoses of hepatitis C and cirrhosis were more likely to be seen.
Our study demonstrated an association between access to GI specialty care and improved survival at 5 years, and this association was present for patients with both high-and low-grade fi brosis. Similar associations between access to specialty care and improved survival have been shown in other specialties, particularly in cardiology, where studies in cardiac patients post hospitalization for myocardial infarction have shown that specialist involvement was also associated with improved mortality ( 4 ) . Th e reasons for these associations are unclear, however. Within gastroenterology and hepatology, subspecialty involvement has been associated with improved processes and some outcomes in a variety of diseases including GI bleeding, diverticulitis, celiac disease, infl ammatory bowel disease, decompensated cirrhosis, ascites, hepatitis C, and hepatocellular carcinoma, although none was able to show a mortality benefi t ( 6-9,11-13 ). A trend toward improved inpatient survival for admitted patients with end-stage liver disease seen by GI subspecialists in the inpatient setting has been reported, although this trend did not reach statistical signifi cance ( 14 ) . Furthermore, local access to GI subspecialty care has been shown to improve chances of receiving a liver transplant ( 15 ) . It must be noted, however, that the association between GI specialty access and improved survival may not be related to GI specialty care exclusively but may represent an overall improvement in mortality, resulting from connection to the healthcare system in general. Patients who receive a diagnosis of liver disease may not have been substantially connected to the VA or other healthcare systems prior to this diagnosis; hence, improvement in mortality may refl ect the combined eff ects of both primary and specialty care of the patients' liver disease and other comorbidities. In addition, patients with low-grade fi brosis would be expected to have low mortality; hence, the fi ndings No GI visit --Yes GI visit -- private insurance or Medicare and opt for medical care in the private sector. We controlled for this misclassifi cation bias, however, by excluding patients with 10 or fewer visits over the study time frame who had no GI visit or inpatient visit during that time. Th is exclusion increases the likelihood that patients in the cohort are primarily cared for within the VA system and minimizes misclassifi cation. Th ird, the use of ICD-9 codes in administrative databases may be inaccurate in representing true disease. Within the VA system, however, ICD-9 codes for the most common diagnoses in our cohort (HCV and cirrhosis) have been validated and have been shown to have high positive predictive values, representing accurate diagnoses ( 18 ) . In addition, our fi nding that patients with >2 GI visits aft er their liver disease diagnosis had an even greater survival benefi t than those with fewer visits provides support for the presence of true liver disease, as patients with inaccurate diagnoses or those without liver disease (for example, HCV antibody-positive patients without positive viral loads) would be less likely to continue to receive ongoing GI-related care. Fourth, we were unable to capture the presence or absence of inpatient GI consultation. Patients with chronic liver disease may present with more advanced complications such as ascites, variceal bleeding, or hepatic encephalopathy, which are initially managed in the inpatient setting with inpatient GI consultation and management. Unfortunately, the VA electronic health record during the bulk of the study time frame did not allow for the reliable identifi cation of access to inpatient GI consultation; hence, we are unable to characterize the eff ect of inpatient access to GI subspecialty care. Fift h, whether or not a patient was referred for a GI visit is an important factor in determining whether patients receive a GI visit. However, data on referrals within the VA system are less robust and, early in the cohort time frame, an electronic referral was not necessary for a patient to receive a GI clinic visit. As a consequence, ~35% of patients who completed a GI clinic visit did not have a referral. Finally, any care provided at VA installations outside VISN 11 would not have been captured by our methodology. Th ere are several strengths to our study. First, our cohort consists of a large number of patients from a diverse geographical background followed over a 10-year time frame, allowing for enough time to observe a survival benefi t. Second, all liver diseases were included with subgroups for hepatitis C and cirrhosis, making the results more broadly generalizable. We also included additional sensitivity analyses of low-grade and high-grade fi brosis in order to determine whether fi ndings were robust to diff erences in severity of liver disease. Th ird, we used propensity score matching to determine survival between patients with and without a GI clinic visit. Propensity score matching is a technique that allows for all the observed predictors in a given observational study to be collapsed into a single predictor ( 20, 29 ) . Th is method has been used successfully in many observational studies to account for the presence of multiple covariates and produces more reliable results by reducing selection bias found in the observed covariates ( 4, 22, 30 ) .
In conclusion, our fi ndings show that, for patients with liver disease, access to GI specialty care in the form of a face-to-face clinic visit was associated with improved survival. Although the reasons for this association are unclear, more research is necessary to determine whether these fi ndings are replicable in other patient populations, such as those with private insurance or those with Medicare/Medicaid, as well as to determine what factors may infl uence these associations. Additional research is also necessary to study and implement new and innovative communication and coordination techniques to improve subspecialty care access for this growing population.
